C
ardiomyocyte ␤ 1 -and ␤ 2 -adrenoceptors mediate the classic increase in cardiac inotropic state after stimulation by endogenous catecholamines. 1 Activation of ␤-adrenergic signaling is limited in time by rapid homologous desensitization, mediated by receptor phosphorylation, including through G-protein-coupled receptor kinases (ie, GRK2 or ␤-adrenoceptor kinase, ␤ARK1) 2 and in the longer term by agonist-elicited decreases in receptor density. 3 In the chronically failing heart, the inotropic response is diminished in the face of elevated circulating catecholamines, in part through decreased ␤ 1 -adrenoceptor mRNA and proteins, 4 -7 increased abundance and activity of ␤ARK, 8 and increased abundance of the inhibitory G protein, G i , which couples receptor stimulation to decreases in intracellular production of cAMP, a key mediator for the contractile effects of ␤-adrenoceptor stimulation. 9 -11 Transgenic models or gene transfer experiments in failing cardiomyocytes highlighted the importance of these signaling molecules in the development of contractile dysfunction and opened new therapeutic avenues for heart failure. Cardiacspecific overexpression of ␤ 2 -adrenoceptor or G␣ s transgenes that positively couple to cAMP formation resulted in enhanced cardiac contraction and responsiveness to catecholamines, at least up to 12 weeks. 12, 13 Adenovirusmediated transfection of ␤ 2 -adrenoceptors or a ␤ARK inhibitor in cardiomyocytes from chronically paced failing rabbit hearts restored cAMP production in these cells after agonist stimulation. 14 However, transgenic mice overexpressing ␤ 1 -adrenoceptors that displayed early enhanced contractility developed cardiac hypertrophy, fibrosis, and heart failure when studied at a later age (beyond 35 weeks). 15 Therefore, short-term benefits of enhancing ␤ 1 -adrenoceptor signaling must be distinguished from potential toxic effects of adrenergic stimulation over longer periods, at least in these animal models. 16 How some or all of these paradigms apply to human heart failure, however, is unknown. In particular, the clinical experience that chronic treatment of heart failure patients with ␤-adrenergic blockers slows the progression of the disease and improves outcomes suggests a more complex regulation of myocardial inotropism by catecholamines. 17 After molecular cloning of a third ␤-adrenoceptor subtype, the ␤ 3 -adrenoceptor, 18 and its detection in human adipocytes, 19 evidence was provided for its functional role in human ventricular myocardium from nonfailing, denervated hearts. 20 In contrast to ␤ 1 -and ␤ 2 -subtypes, stimulation of ␤ 3 -adrenoceptors with ␤ 3 -preferential agonists or norepinephrine (in the presence of full blockade with ␣ 1 -, ␤ 1 -, and ␤ 2 -adrenoceptor antagonists) inhibited cardiac contractility. This effect implicated the inhibitory G protein G i/o , and more recently was shown to involve the production of nitric oxide (NO) by the endothelial isoform of NO synthase expressed within the ventricular myocardium, or eNOS. 21 The regulation of the ␤ 3 -adrenoceptor pathway in the human failing heart, however, is unknown. Here, we first demonstrate the expression of ␤ 3 -adrenoceptors in ventricular myocytes from nondenervated, nonfailing human hearts and show that contrary to ␤ 1 -adrenoceptors, the abundance of ␤ 3 -adrenoceptors increases in ischemic or dilated cardiomyopathic hearts. This is paralleled by increased abundance of G␣ i-2 coupling proteins in the same hearts but decreased expression of eNOS. In addition, we show that these opposite changes in abundance of ␤-adrenoceptor subtypes result in striking impairment of the positive inotropic effect of the nonspecific ␤-adrenoceptor agonist isoprenaline but less attenuation of the negative inotropic effect of the ␤ 3 -preferential adrenoceptor agonist BRL 37344. These findings substantiate the hypothesis that overstimulation of the relatively desensitization-resistant ␤ 3 -adrenoceptor 22 after increased sympathetic tone and norepinephrine release in the setting of heart failure may further decrease cardiac inotropy and open the perspective for correcting the disordered adrenergic regulation of the failing heart with specific antagonists of the human cardiac ␤ 3 -adrenoceptor.
Methods Reverse Transcription-Polymerase Chain Reaction Amplification
Because cDNA synthesis is a critical step for reverse transcriptionpolymerase chain reaction (RT-PCR) quantitation experiments, efforts have been made to optimize reverse transcription for a reproducible maximum efficiency. Total RNA isolated from frozen left ventricular (LV) specimens was reverse transcribed with Superscript II (Gibco BRL) at 45°C for 50 minutes. ␤ 1 -and ␤ 2 -adrenoceptor cDNA was then amplified by PCR (35 cycles) at the following annealing temperatures: 54°C (␤ 2 -AR), 55.5°C (␤ 1 -AR), or 60°C (36B4) (see sequences of primers in Table 1 ). The absence of contamination by genomic DNA was ascertained in parallel amplifications of RT(Ϫ) samples, which always remained negative. The density of ethidium-stained bands, analyzed on 3% agarose gels, was quantified with image-analysis software (ImageJ, NIMH), and data were normalized to the level of transcripts for the housekeeping gene 36B4 (acidic ribosomal phosphoprotein PO). 23 
Western Blotting Experiments
Denatured proteins from human ventricular tissues were separated on 10% SDS-PAGE gels (␤ 3 -AR) or 12% 6 mol/L urea gels (G␣ i-2 ) and transferred on nitrocellulose. Membranes were incubated for 4 hours with the primary antibody (ie, anti-eNOS, Transduction Labs; anti-␤ 3 -adrenoceptors, generously provided by Dr J. Arch, SmithKline-Beecham Pharmaceuticals, Harlow, UK; or anti-G␣ i-2 , a gift from Dr M. Böhm, Universitat zu Köln, Germany), washed in TBST (Tris-buffered saline containing 0.1% Tween 20), incubated with the secondary antibody at 1:10 000, and revealed by chemiluminescence. Densitometric values for each sample were expressed as a percentage of the mean value obtained for the corresponding control (nonfailing) samples analyzed on the same gel.
Immunohistochemistry
Immunohistochemical localization of the ␤ 3 -AR was performed on cryostat sections of human endomyocardial biopsy specimens from failing and nonfailing hearts. The same rat monoclonal anti-␤ 3 -adrenoceptor primary antibody was used, followed by detection with an avidin-biotin complex immunoperoxidase method and diaminobenzidine as chromogen. Control experiments were run in parallel with normal rat IgG as primary antibody.
Contractility Measurements
Ventricular samples were electrically stimulated (0.6 Hz) in a tissue chamber perfused with oxygenated Tyrode's solution (2.7 mmol/L CaCl 2 ; 37Ϯ0.5°C) and tensions recorded at steady state by a mechanoelectric force transducer (Akers, AE 801; SensoNor), as described previously. 24 The cumulative concentrationresponse curves of isoprenaline and the ␤ 3 -preferential agonist BRL 37344 were determined by superfusion with increasing concentrations of the drugs. Changes in tension were expressed as percent increase (or decrease) of baseline (each sample being its own control). To determine agonist potencies from the concentration-response curves, the concentrations producing 50% of maximum effect (EC50) were determined by fitting curves with the Bolzmann equation. pD2 values were calculated according to the equation pD2 ϭϪlog(EC50).
Drugs
Isoprenaline was obtained from Sigma Chemical Co and BRL 37344
Statistical Analysis
Data are presented as meanϮSEM. Statistical significance of the drug effect was assessed by 1-way ANOVA followed by a Dunnett test. Comparison of the concentration-response curves was performed by 2-way ANOVA. Statistically significant differences between groups in terms of mRNA or protein expression were calculated by a Student's t test for unpaired data.
Results

Patient Characteristics
Nonfailing heart tissues were obtained from 3 sources, with the approval of local ethics committees. Thirteen samples of denervated hearts were collected from endomyocardial biopsy specimens in transplanted patients (mean ejection fraction 64.3Ϯ6%). None of these patients showed any histological sign of rejection in biopsy specimens taken in parallel. Table 2 .
Expression of ␤-Adrenoceptor Subtypes in Normal and Failing Hearts
Cardiomyocytes are the predominant cell type within normal human ventricle to express ␤ 1 -and, to a much lesser extent, ␤ 2 -adrenoceptors. The abundance of these 2 subtypes is known to be altered in the failing heart, with a reduction of ␤ 1 -adrenoceptor proteins, 5 whereas ␤ 2 -adrenoceptors are primarily unchanged. 3 Accordingly, we found that the abundance of mRNAs for ␤ 1 -adrenoceptors was reduced by 48.1Ϯ8.5% in failing hearts (nϭ14 patients; 9 ischemic and 5 dilated cardiomyopathies) compared with levels measured in extracts from nonfailing patients (1 denervated and 4 nondenervated hearts; PϽ0.05). In the same extracts, the abundance of ␤ 2 -adrenoceptor mRNAs was unchanged (Pϭ0.08).
Using a monoclonal antibody specific for the human ␤ 3 -adrenoceptor in extracts of nonfailing hearts, we found a single immunodetected band of a size compatible with a glycosylated form of the receptor, as observed in other human tissues. 25 Of note, the abundance of ␤ 3 -adrenoceptor proteins was higher in nonfailing, nondenervated cardiac tissues than in tissues from nonfailing but denervated transplanted hearts ( Figure 1B) . Moreover, compared with levels observed in nonfailing, nondenervated hearts, ␤ 3 -adrenoceptors were significantly increased in failing cardiac tissues from either ischemic or dilated cardiomyopathic hearts ( Figure 1A and 1B). Subsequent analysis of extracts from epicardial, midmyocardial, and subendocardial layers from both ventricles showed no transmural difference in ␤ 3 -adrenoceptor abundance (not shown).
Immunolocalization of ␤ 3 -Adrenoceptors in the Human Ventricle
To identify the specific cell type(s) expressing ␤ 3 -adrenoceptors within the human ventricle, the same antibody was used in immunohistochemical experiments on similar tissue samples (Figure 2) . No staining was detectable above background when the primary antibody was omitted or nonspecific rat IgG was used. However, with the specific antibody, a strong signal was detected in cardiac myocytes from nonfailing, nondenervated ventricular tissue ( Figure  2A) . A light staining was also present in vessels. Consistent with immunoblotted signals as described above, the intensity of cardiomyocyte labeling appeared to be higher in sections 
Moniotte et al ␤ 3 -Adrenoceptors in Failing Heart
of ventricular tissue from dilated or ischemic cardiomyopathic hearts ( Figure 2C and 2E).
Changes in Abundance of G␣ i-2 and eNOS Proteins
Our previous studies 21 had demonstrated that the contractile effect of ␤ 3 -adrenoceptor agonists is mediated, at least in part, through a pertussis toxin-sensitive stimulation of NO production. To assess potential changes in the expression of these signaling molecules in the failing heart, we compared the abundance of G␣ i-2 proteins, the main G␣ i isoform in human ventricle, 11 and eNOS, the NO synthase constitutively expressed in human cardiomyocytes, 21 in failing and nonfailing hearts ( Figure 1C and 1D ). In agreement with previous studies, 9 -11 we found that the level of immunoblotted G␣ i-2 proteins was increased in failing myocardium from ischemic (nϭ11 patients) and dilated (nϭ8 patients) cardiomyopathic hearts compared with nonfailing hearts (nϭ5 patients: 3 nondenervated, 2 denervated) ( Figure 1D ). By contrast, the abundance of eNOS proteins was decreased in ischemic (nϭ16 patients) and dilated (nϭ8 patients) cardiomyopathic hearts compared with nonfailing hearts (nϭ10 patients: 6 nondenervated, 4 denervated) ( Figure 1C) . Again, no transmural difference in eNOS abundance was observed between the various layers of myocardium from both ventricles (not shown).
Contractile Responsiveness to ␤-Adrenergic Agonists
To assess the functional consequences of these expressional changes in ␤-adrenergic signaling molecules, we analyzed the contractile response of human ventricular biopsy specimens both to isoprenaline, a nonspecific ␤-adrenergic agonist, and to BRL 37344, a ␤ 3 -preferential adrenergic agonist, ex vivo.
Basal tension values in nondenervated, nonfailing hearts were 537Ϯ204.3 N in dissected trabeculae (nϭ4) and 63.8Ϯ21.1 N in biopsy specimens (nϭ6), and 675Ϯ157.6 N and 847Ϯ139.4 N in ischemic (nϭ15) and dilated (nϭ16) cardiomyopathic trabeculae, respectively. Variations between trabeculae and biopsy specimens are explained by anatomic differences in sarcomere orientation 24 . In LV samples from nonfailing, nondenervated hearts, isoprenaline produced an increase in absolute contractile tension with a pD2 of 7.52Ϯ0.06 and an effect at 1 mol/L amounting to 370Ϯ69% over basal contractile tone ( Figure 3A) , and BRL 37344 produced a decrease in absolute tension with a pD2 of 9.08Ϯ0.21 and a maximum reduction of 44Ϯ4% below basal contractile tension at 1 mol/L ( Figure 3B ). This negative inotropic effect was attenuated by the specific antagonist of the human ␤ 3 -adrenoceptor, L-748,337 (with 0.1 mol/L L-748,337: Ϫ23Ϯ6.0% [nϭ6]; without L-748,337: Ϫ50.3Ϯ1.8% [nϭ6] of basal tone; PϽ0.01). In trabeculae from failing hearts, however, the positive inotropic effect of 1 mol/L isoprenaline was greatly reduced to 94Ϯ24% and 12Ϯ14% over basal tension in ischemic and dilated cardiomyopathic hearts, respectively ( Figure 3A ) (pD2 7.34Ϯ0.21 and 7.64Ϯ0.15), and the negative inotropic effect of BRL 37344 was attenuated to 32Ϯ8% and 18Ϯ6% below basal tension, respectively ( Figure 3B ) (pD2 8.3Ϯ0.20 and 8.3Ϯ0.23). Therefore, the failing hearts exhibited a loss of responsiveness to both agonists that was more prominent for isoproterenol than for the ␤ 3 -preferential adrenergic agonist BRL 37344 ( Figure 3C ).
Discussion
We demonstrated that in addition to ␤ 1 -and ␤ 2 -adrenoceptors, ␤ 3 -adrenoceptors are expressed in human nonfailing ventricular myocardium. This substantiates our previous observation of a functional response to catecholamines in the human heart through a ␤-adrenergic receptor that is distinct from the ␤ 1 -and ␤ 2 -subtypes. Indeed, contrary to ␤ 1 -and ␤ 2 -adrenoceptor pathways, activation of this receptor by norepinephrine in the presence of ␣ 1 -and ␤ 1 -␤ 2 -antagonists, as well as by ␤ 3 -preferential adrenoceptor agonists such as BRL 37344 20, 21 and CGP 12177 (which also combines antagonistic properties for ␤ 1 -␤ 2 -adrenoceptors), 26 decreases contractile force. Of note, the order of potency of these agonists differs for their lipolytic and inotropic effects, a phenomenon likely due to differences in their specificity for the ␤ 3 -receptor across species and even tissues (for a review, see Gauthier et al 27 ). In addition to specific transcripts, 20 we now identified ␤ 3 -adrenoceptor proteins in human ventricular muscle as observed in other human tissues with the same antibody ( Figure 1A ). The specificity of the antibody for the ␤ 3 -subtype, as opposed to human ␤ 1 -and ␤ 2 -adrenoceptors, was previously ascertained against recombinant human ␤ 1 -␤ 2 -␤ 3 -subtypes heterologously expressed in Chinese hamster ovary (CHO) cells, with no cross-reactivity to ␤ 1 -␤ 2 -subtypes. 25 Of interest, we found a robust expression of the ␤ 3 -adrenoceptor in nonfailing hearts from normal donors, further extending the potential physiological role of this pathway in the innervated myocardium as opposed to denervated, transplanted hearts. In the latter, we also found a downregulation of ␤ 1 -adrenoceptor mRNA (data not shown), although this may be at variance with previous functional results. 28 Moreover, we showed that the ␤ 3 -adrenoceptor is expressed predominantly in human cardiomyocytes ( Figure  2 ), where downstream signaling molecules such as G␣ i-2 and eNOS are colocalized, suggesting a direct rather than paracrine regulation of cardiomyocyte contractility by ␤ 3 -adrenoceptor stimulation. The functional significance of the fainter staining observed in vessels awaits the results of additional studies of human vascular reactivity. A downregulation of ␤ 1 -adrenoceptors is well established in the failing human heart, 5 whereas ␤ 2 -adrenoceptors are primarily unchanged. 3 Accordingly, we found that the abundance of ␤ 1 -(but not ␤ 2 -) adrenoceptor mRNAs was significantly decreased in failing myocardium. Aside from this downregulation, the desensitization of failing myocardium to the positive inotropic effect of catecholamines has been attributed in part to the upregulation of G proteins of the ␣ i isoform that couple to inhibition of adenylyl cyclase. 10 In the present study, as in previous studies, 9 -11 the abundance of G␣ i-2 proteins was increased in failing ventricular myocardium ( Figure 1D ). Because ␤ 1 -adrenoceptors are the predominant positively inotropic ␤-adrenoceptors in cardiac muscle, their downregulation is thought to account for a significant Contractile tension of human ventricular biopsy specimens in response to inotropic amines ex vivo. A, Concentrationdependent positive inotropic effect of nonspecific ␤-adrenoceptor agonist, isoprenaline, in nondenervated nonfailing (Ⅲ; nϭ4 patients) and failing ischemic ('; nϭ6 patients) and dilated (}; nϭ7 patients) cardiomyopathic heart tissues. PϽ0.001 for ischemic and dilated cardiomyopathic hearts vs nonfailing hearts by 2-way ANOVA. B, Concentration-dependent negative inotropic effect of ␤ 3 -preferential agonist, BRL 37344, in nondenervated nonfailing (Ⅲ; nϭ6 patients) and failing ischemic ('; nϭ9 patients) and dilated (}; nϭ9 patients) cardiomyopathic heart tissues. PϽ0.05 for dilated and ischemic hearts vs nonfailing hearts by 2-way ANOVA. C, Attenuation of inotropic responses to 1 mol/L isoprenaline (upper bars) and 1 mol/L BRL 37344 (lower bars) in failing ischemic (ICM) and dilated (DCM) cardiomyopathic heart tissues compared with responses in nonfailing hearts (Normal). Results are normalized to response obtained with 1 mol/L of either agonist in nonfailing hearts, expressed as 100%. Attenuation of isoprenaline responses was significantly more pronounced than that of BRL 37344. Pϭ0.0001 by 2-way ANOVA.
part of the loss of inotropic response to catecholamines in the failing heart. Accordingly, we observed Ͼ75% attenuation of the positive inotropic effect of isoprenaline in ventricular biopsy specimens from ischemic and dilated cardiomyopathic hearts. Moreover, we now show that contrary to ␤ 1 -adrenoceptors, the abundance of the negatively inotropic ␤ 3 -adrenoceptors increases in the failing myocardium. This was apparent both by immunohistochemistry and Western blotting in whole-muscle extracts across the different ventricular layers (Figures 1 and 2 ). That these increased ␤ 3 -adrenoceptors are functional was ascertained from the observation that stimulation of failing heart tissue with ␤ 3 -preferential agonists did produce a negative inotropic effect ex vivo (Figure 3) .
However, changes in contractile response did not strictly parallel those in ␤ 3 -receptor abundance. Despite increased ␤ 3 -adrenoceptors, the negative inotropic effect was blunted in cardiomyopathic tissue compared with responses observed in nonfailing cardiac tissue. This may be explained by concurrent alterations in postreceptor coupling mechanisms in the failing heart. Although intracellular pathways coupling ␤ 3 -adrenoceptor stimulation are still incompletely characterized, we had shown that they involved the production of NO in the human ventricle. 21 Our observation of decreased eNOS expression in failing hearts provides one explanation for the attenuated ␤ 3 -response. However, when compared with responses measured in nonfailing heart, the negative inotropic effect of ␤ 3 -adrenoceptor agonists was more preserved in failing hearts than the ␤ 1 -␤ 2 positive inotropic effect of isoprenaline, thereby potentially producing an imbalance between these inotropically opposed pathways ( Figure 3C ). Aside from the increased receptor abundance, the relative persistence of the ␤ 3 -adrenoceptor response may be related to the resistance of this subtype to homologous desensitization because it lacks the consensus sequences for phosphorylation by GRKs, 22 or to the parallel upregulation of G␣ i-2 proteins, because the coupling of ␤ 3 -adrenoceptors to their functional effect was shown to be sensitive to pertussis toxin. 20 Therefore, the attenuated contractile effect of isoprenaline, a nonspecific ␤ 1 -␤ 2 -␤ 3 -agonist, in failing hearts may integrate a persistent ␤ 3 -adrenoceptor, negatively inotropic effect superimposed on a sharply downregulated ␤1 response. A similar imbalance is even more likely to occur in vivo in the face of increased local and circulating catecholamines, eg, norepinephrine, which has a relatively high affinity for the ␤ 3 -adrenoceptor (unlike the ␤ 2 -subtype). 18 Nevertheless, because they were mostly based on mechanical experiments in vitro, these paradigms will need further rigorous validation in patients.
The concurrent activation of inverse inotropic pathways, mediated by distinct ␤-adrenoceptor subtypes, helps to rationalize previous observations on the regulation of catecholamine responsiveness of the heart in vivo. After our demonstration of the countervailing, negatively inotropic influence of eNOS on the ␤-adrenergic response in isolated cardiomyocytes, 29 others observed that inhibition of cardiac NOS or eNOS gene disruption results in a potentiation of the positive inotropic effect of isoprenaline or dobutamine in dogs, 30 humans, 31 and eNOS-deficient mice. 32 Of note, this potentiation was only apparent in patients with heart failure, 33 where we would anticipate a prevailing influence of the ␤ 3 /NO pathway over ␤ 1 -␤ 2 -signaling, according to our present results. Likewise, a recent study showed that the potentiation of the positive inotropic effect of isoprenaline by NOS inhibition is abolished in mice homozygously deficient for the ␤ 3 -adrenoceptor, 34 confirming the involvement of this subtype in the NO-dependent regulation of catecholamine responsiveness in vivo. The ␤ 3 -adrenoceptor pathway may subserve different physiological functions in the heart ( Figure  4 ). In the normal heart, it may exert a negative counterregulation against excessive positive inotropic stimulation, thereby moderating oxygen consumption, preventing calcium overload and ultimately cardiomyocyte toxicity, as exemplified by the phenotype of ␤ 1 -adrenoceptor-overexpressing mice. 15 At early stages of cardiac dysfunction, endogenous NO production may, in addition to attenuating ␤ 1 -␤ 2 -adrenergic inotropic responses, improve diastolic relaxation, 35 thereby compensating systolic dysfunction by increasing diastolic reserve. In terminally failing hearts, the residual negative inotropic effect may become maladaptive and aggravate systolic dysfunction (Figure 4 , right). More insights into these potential roles and their impact on the clinical use of ␤-blockers should be gained from linear studies of animal models and patients with progressive heart failure as new specific antagonists for the human ␤ 3 -adrenoceptor become available.
